Dr. Shahabi is principal investigator for the following clinical protocols currently open at Northwestern:
NU 15G03 Partial wave spectroscopy (PWS) for ovarian cancer risk stratification and early detection among patients with high-risk heritable predisposition: developing standard operating procedures for automated PWS and a prediction rule for ovarian cancer screening
GOG 0225 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Progression-Free Survival?
GOG 0238 A randomized trial of pelvic irradiation with or without concurrent weekly cisplatin in patients with pelvic-only recurrence of carcinoma of the uterine corpus
NRG-GY004 A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
NRG-GY005 A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)
NRG-GY006 A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
To learn more about the clinical trials offered at Northwestern, please visit our Cancer Center website